Sector News

Phil Schiller, Apple's marketing chief, is now a director of Illumina

August 1, 2016
Life sciences

Phil Schiller, Apple’s marketing chief, is now a director of Illumina, one of the most important companies in gene sequencing.

Illumina has an enormous presence in the life science industry. It makes the machines and develops technology used for genetic testing, and counts companies like 23andMe as customers. It has a market capitalization of $25 billion.

If you’ve had your genes sequenced, in one of those consumer genetic tests like 23andMe for instance, it was most likely on an Illumina machine. 90% of human genetic sequencing takes place on Illumina machines.

Earlier this year, Apple’s ResearchKit platform — which is being explored for uses in drug development — began to support studies that use 23andme genetic information.

“Illumina is like the ruler of this whole universe and no one knows that,” 23andMe’s CEO Anne Wojcicki told Fast Company.

“Phil’s track record and global experience in bringing world-class products to market will help guide us as we continue to develop innovative new solutions for our customers,” Francis deSouza, Illumina president said in a statement.

Apple has health ambitions
Schiller has been with Apple since 1997 and works to define the company’s product lines and strategy. He’s a key advisor to CEO Tim Cook and frequently presents the newest iPhone at Apple keynote presentations.

Apple as a company has a deep interest in health and its Apple Watch is a way to break into the medical world. Apple executives talk about simplifying health care as a major focus and mission — it’s even hired nurses to staff labs to do round-the-clock biometric testing.

“We believe that health is something that is a huge problem in the world, and we think it is ripe for simplicity and a new view, and we’d like to contribute to that,” Apple CEO Tim Cook said at a conference earlier this year.

Apple’s health division reports to Apple COO Jeff Williams, not Schiller. And Schiller joining his first board of directors in the health space could signal an expansion of Apple’s medical ambitions given his product focus.

Previously, Apple was looking to hire a medical privacy specialist who could consult on mergers and acquisitions, and hired the CEO of Sage Bionetworks, which handles much of the consent and back-end functions for Apple’s health software.

Source: Illumina

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.